FDA Approves The First Treatment For Dementia Of Parkinson's Disease

... The Food and Drug Administration (FDA) today approved Exelon (rivastigmine tartrate) for the treatment of mild to moderate dementia (chronic loss or impairment of intellectual capacity) associated with Parkinson's disease, a disorder of the central nervous system. Exelon was previously approved for the treatment of mild to moderate dementia of the Alzheimer's type. [click link for full article] ...